SGMT

SGMT

USD

Sagimet Biosciences Inc. Series A Common Stock

$7.520-0.010 (-0.133%)

السعر في الوقت الحقيقي

Healthcare
التكنولوجيا الحيوية
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$7.530

الأعلى

$7.670

الأدنى

$7.020

الحجم

0.13M

أساسيات الشركة

القيمة السوقية

244.6M

الصناعة

التكنولوجيا الحيوية

البلد

United States

إحصاءات التداول

متوسط الحجم

0.57M

البورصة

NGM

العملة

USD

نطاق 52 أسبوعاً

الأدنى $1.73الحالي $7.520الأعلى $11.41

أخبار ذات صلة

GlobeNewswire

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical trial in acne in China conducted by license partner Ascletis Ascletis announced completion of

عرض المزيد
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
Analyst Upgrades

Clear Street Initiates Coverage On Sagimet Biosciences with Buy Rating, Announces Price Target of $29

Clear Street analyst Kaveri Pohlman initiates coverage on Sagimet Biosciences with a Buy rating and announces Price Target of $29.

عرض المزيد
Clear Street Initiates Coverage On Sagimet Biosciences with Buy Rating, Announces Price Target of $29
GlobeNewswire

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

SAN MATEO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and

عرض المزيد
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
GlobeNewswire

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic

عرض المزيد
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.